Drug Profile
MIV 150/zinc acetate
Alternative Names: MIV 150/Zinc Acetate/Carrageenan; PC-1005; Zinc acetate/MIV-150Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Medivir AB
- Developer Population Council (USA)
- Class Acetates; Antivirals; Heavy metals
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in HIV-infections(Prevention) in USA (Vaginal, Gel)
- 30 Jan 2018 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV infections (Prevention) (Rectal) in April 2018 (NCT03408899)
- 08 Jan 2014 Preclinical trials in HIV infections (prevention) in USA (Vaginal) prior to January 2014